Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 4/20 | 0.38 |
| ▸ | EGFR | P00533 | 8/20 | 0.35 |
| ▸ | INSR | P06213 | 5/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 5/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511949 | 0.89 | NOS3 (0.38) | WEE1EGFRINSRALKMET | |
| SCHEMBL188629 | 0.89 | WEE1 (0.40) | WEE1EGFRINSRALKMET | |
| SCHEMBL215812 | 0.84 | WEE1 (0.37) | WEE1EGFRINSRMETTNK2 | |
| SCHEMBL8513938 | 0.82 | WEE1 (0.48) | WEE1EGFRTNK2 | |
| SCHEMBL8511197 | 0.82 | WEE1 (0.46) | WEE1ALKMETTNK2 | |
| SCHEMBL8511945 | 0.81 | SRC (0.48) | WEE1EGFRALKMETTNK2 | |
| SCHEMBL8509293 | 0.81 | WEE1 (0.40) | WEE1EGFR | |
| SCHEMBL213397 | 0.80 | WEE1 (0.49) | WEE1TNK2 | |
| SCHEMBL213088 | 0.80 | SRC (0.49) | WEE1EGFRALKMETTNK2 | |
| SCHEMBL8511920 | 0.80 | SRC (0.42) | WEE1EGFRTNK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | WEE1 1/4885EGFR 425/4885INSR 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.